Covid Positive	Covid negative		Percent with feature	Percent COVID positive	Hazards ratio	95% CI	P	Comments
ALL PATIENTS
Sarcoidosis	66	1906	1972		3.35%	9.15	2.249-37.253	0.002
Cancer	2	545	547		0.37%
LOCAL
OH/KY/IN	3	538	541		0.55%	1.5166	0.2544-9.041		Cincinnati Clinic patients
Cancer	2	545	547		0.37%				Sarc versus cancer
Sarc patients
Male	19	495	514	26.18%	3.70%	1.14	0.675-1.923	>0.10
Female	47	1402	1449	73.82%	3.24%				9 no sex indicated
Black	11	371	382	20.07%	2.88%	0.796	0.4209-1.5066	>0.10
White	55	1466	1521	79.93%	3.62%				9 patients biracial
Roommate with COVID
yes	21	17	38	1.94%	55.26%	23.6772	15.769-35.5514	<0.0001
no	45	1883	1928	98.22%	2.33%
Health care provider
Yes	12	197	209	10.65%	5.74%	1.8565	1.0099-3.4127	0.0464
no	54	1692	1746	88.95%	3.09%
Current meds
Prednisone	24	755	779	39.50%	3.08%	0.8751	0.5343-1.4332	>0.10
No prednisone	42	1151	1193	60.50%	3.52%
Prednisone >10 mg or more	13	361	374	18.97%	3.48%	1.048	0.5774-1.9022	>0.10
Prednisone < 10 mg	53	1545	1598	81.03%	3.32%
Plaquenil	7	239	246	12.47%	2.85%	0.8324	0.3846-1.8016	>0.10
No plaquenil	59	1667	1726	87.53%	3.42%
anti-TNF	6	183	189	9.58%	3.17%	0.9434	0.4131-2.1542	>0.10
no anti-TNF	60	1723	1783	90.42%	3.37%
Cytotoxic	21	537	558	28.30%	3.76%	1.1826	0.7111-1.9666	>0.10
No cytotoxic	45	1369	1414	71.70%	3.18%
Rituximab	6	42	48	2.43%	12.50%	4.0083	1.8213-8.8217	0.0006
No rituximab	60	1864	1924	97.57%	3.12%
Underlying
COPD	12	321	333	16.89%	3.60%	1.0938	0.5917-2.0217	>0.10
	54	1585	1639	83.11%	3.29%
Diabetes	5	292	297	15.06%	1.68%	0.4623	0.1873-1.1408	0.0941
	61	1614	1675	84.94%	3.64%
Heart disease	8	254	262	13.29%	3.05%	0.9002	0.4348-1.8637	>0.10
	58	1652	1710	86.71%	3.39%
Hypertension	15	480	495	25.10%	3.03%	0.8776	0.498-1.5466	>0.10
	51	1426	1477	74.90%	3.45%
Organ involved
Lung	58	1596	1654	83.87%	3.51%	1.3939	0.6721-2.8907	>0.10
	8	310	318	16.13%	2.52%
Cardiac sarc	12	278	290	14.71%	4.14%	1.3303	0.7206-2.4557	>0.10
	54	1628	1682	85.29%	3.21%
Neuro sarc	11	184	195	9.89%	5.64%	1.8228	0.9704-3.4229	0.0619
	55	1722	1777	90.11%	3.10%
Origin
US	50	1551	1601	81.19%	3.12%	0.7516	0.4269-1.3232	>0.10
non US	15	346	361	18.31%	4.16%				No country entered: 10
OH/KY/IN	3	538	541	27.43%	0.55%
	63	1368	1431	72.57%	4.40%
Sarcoid age
Covid Positive							54.5 ± 11.39 years	0.088
Covid negative							53.0 ± 9.60 years
COVID outcome	Home	Hospital	ICU	Ventilator
Sarc	44	9	3	0
Cancer	1	1	0	0
Sarc ≥ 5 yr	48	1274	1322	67.35%	3.63%	1.3321	0.7629-2.359	>0.01
Sarc < 5 yr	16	571	587	29.90%	2.73%
									Hospital considered bad outcome
COVID positive	Home	Hospital							Hazard ration for
Prednisone									Hospitalization
Yes	20	4	24	1.22%	83.33%	0.875	0.2941-2.6036	>0.10
No	34	8	42	2.14%	80.95%
If prednisone
Prednisone ≥ 10 mg	11	2	13	19.70%	15.38%	0.8154	0.2027-3.2794	>0.10
Prednisone < 10mg	43	10	53	80.30%	18.87%
Infliximab
Yes	4	2	6	0.31%	66.67%	0.8154	0.2027-3.2794	>0.10
No	50	10	60	3.06%	83.33%
Plaquenil
Yes	6	1	7	0.36%	85.71%	0.7662	0.1156-5.9785	>0.10
No	48	11	59	3.01%	81.36%
Cytotoxic
Yes	14	7	21	1.07%	66.67%	3	1.0773-83539	0.0355
No	40	5	45	2.29%	88.89%
Rituximab
Yes	6	0	6	0.31%	100.00%	0.3486	0.02303-5.2723	>0.10
No	48	12	60	3.06%	80.00%

* 9 patients did not indicate sex.

† 9 patients biracial

¶ Included inflixiamb, adlimumab, and biosimilars

§ Included methotrexate, azathioprine, mycophenolate, and leflunomide

** 63 patients did not provide information regarding duration of disease.

UC: University of Cincinnati clinic